Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 6/20 | 0.50 |
| ▸ | MYC | P01106 | 1/20 | 0.33 |
| ▸ | WDR5 | P61964 | 1/20 | 0.33 |
| ▸ | CCNE2 | O96020 | 5/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.31 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.31 |
| ▸ | CDK1 | P06493 | 4/20 | 0.31 |
| ▸ | CDK4 | P11802 | 4/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.31 |
| ▸ | CCND1 | P24385 | 4/20 | 0.31 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.31 |
| ▸ | CCND2 | P30279 | 2/20 | 0.30 |
| ▸ | CCND3 | P30281 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3467464 | 0.82 | CDK2 (0.54) | CDK2MYCWDR5CCNE2CCNE1 | |
| SCHEMBL7080405 | 0.76 | CDK2 (0.31) | CDK2 | |
| SCHEMBL6196179 | 0.73 | CDK2 (0.52) | CDK2CCNE2CCNE1CCNB2CDK1 | |
| SCHEMBL6196472 | 0.71 | CCNE1 (0.52) | CDK2CCNE2CCNE1CCNB2CDK1 | |
| SCHEMBL6179556 | 0.70 | CDK2 (0.59) | CDK2MYCWDR5CCNE2CCNE1 | |
| SCHEMBL960172 | 0.67 | CDK2 (1.00) | CDK2CCNE2CCNE1CCNB2CDK1 | |
| SCHEMBL7080407 | 0.66 | — | — | |
| SCHEMBL6198002 | 0.65 | CDK2 (0.60) | CDK2CCNE2CCNE1CCNB2CDK1 | |
| SCHEMBL3467465 | 0.65 | CDK2 (0.76) | CDK2CCNE2CCNE1CCNB2CDK1 | |
| SCHEMBL1025148 | 0.62 | MYC (0.47) | CDK2MYCWDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303512-B1 | PROCESS FOR PREPARING ARYLACETYLAMINOTHIAZOLES | BRISTOL MYERS SQUIBB CO (US) | 2005-07-20 | — | — | EP | claimed |
| JP-2004505079-A | — | — | 2004-02-19 | — | — | JP | claimed |
| US-20030216440-A1 | Process for preparing arylacetylaminothiazoles | CHEN BANG-CHI (US) | 2003-11-20 | — | — | US | claimed |
| US-6613911-B2 | Reaction of haloarylacetic acids or esters with olefins to give vinylarylacetic acids or esters, oxidation with an oxidizing reagent gives formylarylacetic acids or esters | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-02 | — | — | US | claimed |
| EP-1303512-A1 | PROCESS FOR PREPARING ARYLACETYLAMINOTHIAZOLES | Bristol-Myers Squibb Company (US) | 2003-04-23 | — | — | EP | claimed |
| US-20020072609-A1 | Process for preparing arylacetylaminothiazoles | CHEN BANG-CHI (US) | 2002-06-13 | — | — | US | claimed |
| US-6392053-B2 | INCLUDES REACTING HALOARYLACETIC ACIDS OR ESTERS WITH OLEFINS TO GIVEN VINYLACRYLACETIC ACIDS OR ESTERS, FOLLOWED BY OXIDATION TO FORM THE FORMYLARYLACETIC ACID INTERMEDIATE; CYCLIN DEPENDENT KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2002-05-21 | — | — | US | claimed |
| WO-2002010161-A1 | PROCESS FOR PREPARING ARYLACETYLAMINOTHIAZOLES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-02-07 | — | — | WO | claimed |
| US-20010004639-A1 | Process for preparing arylacetylaminothiazoles | BRISTOL-MYERS SQUIBB COMPANY | 2001-06-21 | — | — | US | claimed |
| EP-1303512-B1 | PROCESS FOR PREPARING ARYLACETYLAMINOTHIAZOLES | BRISTOL MYERS SQUIBB CO (US) | 2005-07-20 | — | — | EP | disclosed |
| US-20030216440-A1 | Process for preparing arylacetylaminothiazoles | CHEN BANG-CHI (US) | 2003-11-20 | — | — | US | disclosed |
| US-6613911-B2 | Reaction of haloarylacetic acids or esters with olefins to give vinylarylacetic acids or esters, oxidation with an oxidizing reagent gives formylarylacetic acids or esters | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-02 | — | — | US | disclosed |
| EP-1303512-A1 | PROCESS FOR PREPARING ARYLACETYLAMINOTHIAZOLES | Bristol-Myers Squibb Company (US) | 2003-04-23 | — | — | EP | disclosed |
| US-20020072609-A1 | Process for preparing arylacetylaminothiazoles | CHEN BANG-CHI (US) | 2002-06-13 | — | — | US | disclosed |
| US-6392053-B2 | INCLUDES REACTING HALOARYLACETIC ACIDS OR ESTERS WITH OLEFINS TO GIVEN VINYLACRYLACETIC ACIDS OR ESTERS, FOLLOWED BY OXIDATION TO FORM THE FORMYLARYLACETIC ACID INTERMEDIATE; CYCLIN DEPENDENT KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2002-05-21 | — | — | US | disclosed |
| WO-2002010161-A1 | PROCESS FOR PREPARING ARYLACETYLAMINOTHIAZOLES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-02-07 | — | — | WO | disclosed |
| US-20010004639-A1 | Process for preparing arylacetylaminothiazoles | BRISTOL-MYERS SQUIBB COMPANY | 2001-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216440-A1 | Process for preparing arylacetylaminothiazoles | CCNI, CCNT1, CCNA1 | CDK2 5/4885MYC 1432/4885WDR5 2649/4885 |
| US-20020072609-A1 | Process for preparing arylacetylaminothiazoles | CCNT1, CCNI, CCNA1 | CDK2 6/4885MYC 1468/4885WDR5 3329/4885 |
| US-20010004639-A1 | Process for preparing arylacetylaminothiazoles | CCNI, CCNA1, CCNT1 | CDK2 5/4885MYC 1218/4885WDR5 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.